In this issue

Jonathan Tobin: Defending the Right to a Jewish State

Heather Hale: Compliment your kids without giving them big heads

Megan Shauri: 10 ways you are ruining your own happiness

Carolyn Bigda: 8 Best Dividend Stocks for 2015

Kiplinger's Personal Finance editors: 7 Things You Didn't Know About Paying Off Student Loans

Samantha Olson: The Crucial Mistake 55% Of Parents Are Making At Their Baby's Bedtime

Densie Well, Ph.D., R.D. Open your eyes to yellow vegetables

The Kosher Gourmet by Megan Gordon With its colorful cache of purples and oranges and reds, COLLARD GREEN SLAW is a marvelous mood booster --- not to mention just downright delish
April 18, 2014

Rabbi Yonason Goldson: Clarifying one of the greatest philosophical conundrums in theology

Caroline B. Glick: The disappearance of US will

Megan Wallgren: 10 things I've learned from my teenagers

Lizette Borreli: Green Tea Boosts Brain Power, May Help Treat Dementia

John Ericson: Trying hard to be 'positive' but never succeeding? Blame Your Brain

The Kosher Gourmet by Julie Rothman Almondy, flourless torta del re (Italian king's cake), has royal roots, is simple to make, . . . but devour it because it's simply delicious

April 14, 2014

Rabbi Dr Naftali Brawer: Passover frees us from the tyranny of time

Greg Crosby: Passing Over Religion

Eric Schulzke: First degree: How America really recovered from a murder epidemic

Georgia Lee: When love is not enough: Teaching your kids about the realities of adult relationships

Cameron Huddleston: Freebies for Your Lawn and Garden

Gordon Pape: How you can tell if your financial adviser is setting you up for potential ruin

Dana Dovey: Up to 500,000 people die each year from hepatitis C-related liver disease. New Treatment Has Over 90% Success Rate

Justin Caba: Eating Watermelon Can Help Control High Blood Pressure

The Kosher Gourmet by Joshua E. London and Lou Marmon Don't dare pass over these Pesach picks for Manischewitz!

April 11, 2014

Rabbi Hillel Goldberg: Silence is much more than golden

Caroline B. Glick: Forgetting freedom at Passover

Susan Swann: How to value a child for who he is, not just what he does

Cameron Huddleston: 7 Financial Tasks You Should Tackle Right Now

Sandra Block and Lisa Gerstner: How to Profit From Your Passion

Susan Scutti: A Simple Blood Test Might Soon Diagnose Cancer

Chris Weller: Have A Slow Metabolism? Let Science Speed It Up For You

The Kosher Gourmet by Diane Rossen Worthington Whitefish Terrine: A French take on gefilte fish

April 9, 2014

Jonathan Tobin: Why Did Kerry Lie About Israeli Blame?

Samuel G. Freedman: A resolution 70 years later for a father's unsettling legacy of ashes from Dachau

Jessica Ivins: A resolution 70 years later for a father's unsettling legacy of ashes from Dachau

Kim Giles: Asking for help is not weakness

Kathy Kristof and Barbara Hoch Marcus: 7 Great Growth Israeli Stocks

Matthew Mientka: How Beans, Peas, And Chickpeas Cleanse Bad Cholesterol and Lowers Risk of Heart Disease

Sabrina Bachai: 5 At-Home Treatments For Headaches

The Kosher Gourmet by Daniel Neman Have yourself a matzo ball: The secrets bubby never told you and recipes she could have never imagined

April 8, 2014

Lori Nawyn: At Your Wit's End and Back: Finding Peace

Susan B. Garland and Rachel L. Sheedy: Strategies Married Couples Can Use to Boost Benefits

David Muhlbaum: Smart Tax Deductions Non-Itemizers Can Claim

Jill Weisenberger, M.S., R.D.N., C.D.E : Before You Lose Your Mental Edge

Dana Dovey: Coffee Drinkers Rejoice! Your Cup Of Joe Can Prevent Death From Liver Disease

Chris Weller: Electric 'Thinking Cap' Puts Your Brain Power Into High Gear

The Kosher Gourmet by Marlene Parrish A gift of hazelnuts keeps giving --- for a variety of nutty recipes: Entree, side, soup, dessert

April 4, 2014

Rabbi David Gutterman: The Word for Nothing Means Everything

Charles Krauthammer: Kerry's folly, Chapter 3

Amy Peterson: A life of love: How to build lasting relationships with your children

John Ericson: Older Women: Save Your Heart, Prevent Stroke Don't Drink Diet

John Ericson: Why 50 million Americans will still have spring allergies after taking meds

Cameron Huddleston: Best and Worst Buys of April 2014

Stacy Rapacon: Great Mutual Funds for Young Investors

Sarah Boesveld: Teacher keeps promise to mail thousands of former students letters written by their past selves

The Kosher Gourmet by Sharon Thompson Anyone can make a salad, you say. But can they make a great salad? (SECRETS, TESTED TECHNIQUES + 4 RECIPES, INCLUDING DRESSINGS)

April 2, 2014

Paul Greenberg: Death and joy in the spring

Dan Barry: Should South Carolina Jews be forced to maintain this chimney built by Germans serving the Nazis?

Mayra Bitsko: Save me! An alien took over my child's personality

Frank Clayton: Get happy: 20 scientifically proven happiness activities

Susan Scutti: It's Genetic! Obesity and the 'Carb Breakdown' Gene

Lecia Bushak: Why Hand Sanitizer May Actually Harm Your Health

Stacy Rapacon: Great Funds You Can Own for $500 or Less

Cameron Huddleston: 7 Ways to Save on Home Decor

The Kosher Gourmet by Steve Petusevsky Exploring ingredients as edible-stuffed containers (TWO RECIPES + TIPS & TECHINQUES)

Jewish World Review

Fallen IPOs to Invest in Now

By Kathy Kristof

(Kathy Kristof is a Contributing Editor for Kiplinger's Personal Finance)

George Putnam, editor of the Turnaround Letter, is always on the lookout for an investment bargain. "We don't like to pay full price for anything," he says.

That's one of the reasons he shuns initial public offerings but starts to troll through the ranks of these companies a few months -- or even a few years -- after they first sell stock to the public. After the excitement of a new offering dies down, so do the stock prices, he says. In fact, it's not unusual for a once-hot IPO to sell for a fraction of its first-day value within a few years of going public. When the companies are profitable or have compelling business models, that can be a signal to buy. "If something has gone to half the offering price, it starts to interest me," says Putnam.

Here are four companies that went public less than five years ago but look like bargains today.

Intrepid Potash (symbol IPI) went public in April 2008 at $32 per share and sold for as much as $76. But the stock has been sliding since the financial crisis broke late that year, and it plunged again this May after the company said it would not meet analysts' growth expectations in 2012. Shares of the Denver-based fertilizer producer now trade at $20.94 -- a bargain price, says Morningstar analyst Jeffrey Stafford (all prices and related data are as of June 20).


Every weekday JewishWorldReview.com publishes what many in the media and Washington consider "must-reading". In addition to INSPIRING stories, HUNDREDS of columnists and cartoonists regularly appear. Sign up for the daily update. It's free. Just click here.

Intrepid is compelling for two reasons, Stafford says. First, the company is in the process of adding a new mine to the three it already has in New Mexico; the new facility could boost Intrepid's output by some 20%. The mine is also likely to cut Intrepid's overall cost of production, which could give it an edge over its competition. Intrepid already has a geographic edge over many of its Canadian competitors, such as Potash Corp. of Saskatchewan. Because Intrepid's New Mexico mines are located closer to its customers in the West and Midwest, it spends less shipping its products.

Even though analysts expect Intrepid's earnings to grow at a blistering annualized pace of 27% over the next three to five years, the stock sells for just 16 times estimated 2012 earnings. Stafford thinks the stock is worth $28 today -- about 34% more than its current price.

NetSpend Holdings (NTSP) markets prepaid debit cards to the roughly 60 million Americans who don't have traditional banking relationships. Employers or consumers can load the cards with automatic deposits, paychecks or cash and then use them like ordinary debit cards. The Austin, Tex., company went public two years ago at $11 a share. Its stock climbed to as high as $16 last year but then plunged when the company's growth stalled. It now trades at $ 8.76.

But NetSpend has resumed its growth trajectory, having recently signed deals to provide its cards through Family Dollar Stores and PayPal. Like Intrepid, NetSpend looks attractive on a price-to-growth-rate basis. The shares sell for 16 times projected 2012 earnings, while analysts expect annualized earnings growth of 21% over the next few years. Greg Smith, an analyst at Sterne Agee, thinks the shares will sell for $10 within a year.

Safe Bulkers (SB) is more a value play than a growth story, says Putnam. The Athens-based cargo shipping firm went public in June 2008 at $19 a share and now trades at $6.11. The company has been hurt by weak pricing, thanks to the tepid world economy. But people still need the coal, grain and iron ore that its 20 ships transport. Safe Bulkers' longstanding expansion plans will bring nine more ships online over the next few years.

Safe Bulkers is seen as a lackluster grower; analysts see average profit gains of 5% annually over the next few years, though the company's profits have been slipping in recent years. But Putnam says the stock could take off if world economies stabilize and start growing.

Meanwhile, the company has solid financials and pays a 60 cent annual dividend. At the stock's depressed price, that translates into a mouthwatering yield of 9.8%. That may be a bit too mouthwatering, suggesting that the dividend might be at risk. But Putnam thinks the dividend is safe. He says the company could finance the payouts by borrowing against four new ships that it expects to receive this year. Nonetheless, Safe Bulkers' fate is closely tied to the overall global economy, so the stock is speculative.

Vanguard Health Systems (VHS), which went public in June 2011 at $18 a share, buys troubled hospitals and attempts to turn them around. The Nashville company has been hard hit by worries that the Affordable Care Act might be overturned. The reform law's requirement that everyone buy health insurance helps hospitals because they spend millions each year providing care for uninsured emergency patients. With the Supreme Court set to rule within weeks on whether insurance mandates are constitutional, Vanguard's stock trades at $8.20 -- a fraction of the IPO price.

But the company's revenues are growing at a double-digit pace, and profits are surging. In the third quarter of fiscal 2012, Vanguard earned $44 million, or 55 cents per share, compared with $2.8 million, or 5 cents per share, in the third quarter of fiscal 2011. The company has substantial debt, which is a risk, Putnam says. But the potential is great. Citigroup analyst Gary Taylor expects the company to earn 71 cents per share this year and projects that the stock will sell for $12 within 12 months.

Sign up for the daily JWR update. It's free. Just click here.

Interested in a private Judaic studies instructor — for free? Let us know by clicking here.

Comment by clicking here.

All contents copyright 2012 The Kiplinger Washington Editors, Inc. Distributed by Tribune Media Services. All rights reserved.